http://www.prnewswire.com/news-rele...ies-complete-patient-enrolment-290203621.html
'
SYDNEY, January 29, 2015 /PRNewswire/ --
Combined data from more than 1,000 patients being collected to assess overall survival (OS) benefit of adding first-line SIR-Spheres® Y-90 resin microspheres treatment to a current chemotherapy regimen for inoperable metastatic colorectal cancer (mCRC) Sirtex Medical Limited (ASX:SRX) today announced the completion of patient enrolment in FOXFIRE and FOXFIRE Global, two large multi-centre studies that added liver-directed radiation therapy with SIR-Spheres Y-90 resin microspheres to a current standard of care chemotherapy regimen in the first-line treatment of more than 560 patients recently diagnosed with inoperable metastatic colorectal cancer (mCRC).' .................. etc
FOXFIRE and FOXFIRE Global Studies Complete Patient Enrolment
Add to My Watchlist
What is My Watchlist?